January 13, 2017
Biogen Presents New ENDEAR Data Showing SPINRAZA (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation
Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent...
December 29, 2016
Please join Cure SMA, MDA and representatives from Biogen to learn more about SPINRAZA™ (nusinersen). As you know, SPINRAZA recently received FDA approval in the U.S. for the treatment of Spinal Muscular Atrophy (SMA) in pediatric and adult patients. In order to receive an update on SPINRAZA, please join this webcast, which is intended...
December 23, 2016
Biogen provided the following statement on the approval of Spinraza for SMA:
Dear Members of the SMA Community,
Today, the SMA community achieved a goal that would not have been possible without the support and dedication of the families, physicians and researchers who have passionately pursued a treatment for Spinal Muscular...